Press Releases Latest May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting Press Releases Year None202420232022202120202019201820172016201520142013 Mar 30, 2017 Theratechnologies to Announce Financial Results for the First Quarter of 2017 Mar 06, 2017 Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories Mar 01, 2017 Theratechnologies Holds Investment Community Meeting and Provides Updated Financial Guidance for its Fiscal Year 2017 Mar 01, 2017 Theratechnologies to Host Investment Community Webcast on March 1, 2017 Feb 24, 2017 Theratechnologies to Host Investment Community Webcast on March 1, 2017 Feb 15, 2017 Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab Feb 14, 2017 Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab Feb 08, 2017 Theratechnologies Announces Financial Results for Fiscal Year 2016 Dec 05, 2016 Theratechnologies closes its offering of common shares Nov 25, 2016 Theratechnologies Announces the Filing of a Final Short Form Prospectus First page « Previous page ‹ … Page 24 Page 25 Page 26 Page 27 Current page 28 Page 29 Page 30 Page 31 Page 32 … Next page › Last page » Displaying 271 - 280 of 361
May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Mar 06, 2017 Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories
Mar 01, 2017 Theratechnologies Holds Investment Community Meeting and Provides Updated Financial Guidance for its Fiscal Year 2017
Feb 15, 2017 Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Feb 14, 2017 Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab